DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Vraylar…Original Article
FDA Approves Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression
